AtonRa Partners Sells 1,747 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

AtonRa Partners lowered its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 10.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 14,715 shares of the company’s stock after selling 1,747 shares during the quarter. PROCEPT BioRobotics accounts for 1.2% of AtonRa Partners’ portfolio, making the stock its 21st biggest position. AtonRa Partners’ holdings in PROCEPT BioRobotics were worth $617,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP bought a new stake in PROCEPT BioRobotics during the 3rd quarter valued at $26,404,000. Vanguard Group Inc. raised its position in PROCEPT BioRobotics by 10.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,074,891 shares of the company’s stock valued at $133,697,000 after purchasing an additional 385,271 shares during the last quarter. American Century Companies Inc. lifted its holdings in PROCEPT BioRobotics by 14.2% in the 3rd quarter. American Century Companies Inc. now owns 655,295 shares of the company’s stock worth $21,500,000 after buying an additional 81,534 shares during the period. Dark Forest Capital Management LP bought a new stake in shares of PROCEPT BioRobotics in the 3rd quarter worth approximately $583,000. Finally, Barclays PLC increased its stake in shares of PROCEPT BioRobotics by 225.3% during the third quarter. Barclays PLC now owns 51,613 shares of the company’s stock valued at $1,692,000 after buying an additional 35,746 shares during the period. Hedge funds and other institutional investors own 89.46% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Wells Fargo & Company lifted their price target on shares of PROCEPT BioRobotics from $44.00 to $47.00 and gave the company an “overweight” rating in a report on Tuesday, January 9th. Truist Financial boosted their price target on shares of PROCEPT BioRobotics from $55.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $46.00.

PROCEPT BioRobotics Stock Up 0.4 %

PRCT traded up $0.22 during trading on Monday, reaching $52.05. The stock had a trading volume of 593,637 shares, compared to its average volume of 501,226. The company has a current ratio of 7.63, a quick ratio of 6.77 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.68 billion, a price-to-earnings ratio of -23.44 and a beta of 1.01. The stock’s 50 day moving average is $49.33 and its two-hundred day moving average is $42.77. PROCEPT BioRobotics Co. has a one year low of $24.83 and a one year high of $54.79.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Tuesday, February 27th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.10). PROCEPT BioRobotics had a negative return on equity of 46.59% and a negative net margin of 77.75%. The business had revenue of $43.58 million during the quarter, compared to the consensus estimate of $41.79 million. During the same quarter in the previous year, the business earned ($0.56) earnings per share. The firm’s revenue was up 83.3% compared to the same quarter last year. As a group, analysts expect that PROCEPT BioRobotics Co. will post -2 earnings per share for the current year.

Insider Activity

In related news, CFO Kevin Waters sold 22,349 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $50.16, for a total value of $1,121,025.84. Following the sale, the chief financial officer now owns 33,523 shares in the company, valued at approximately $1,681,513.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CFO Kevin Waters sold 22,349 shares of PROCEPT BioRobotics stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $50.16, for a total value of $1,121,025.84. Following the completion of the transaction, the chief financial officer now owns 33,523 shares of the company’s stock, valued at approximately $1,681,513.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Alaleh Nouri sold 14,694 shares of the company’s stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $49.97, for a total transaction of $734,259.18. Following the completion of the transaction, the executive vice president now owns 47,351 shares in the company, valued at approximately $2,366,129.47. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 94,149 shares of company stock worth $4,653,720. Insiders own 19.60% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).